Aethlon Medical, Inc. (AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projects Agency (DARPA) has exercised an option agreement to proceed with year-three of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.The third year of Aethlon's DLT contract contains eight milestones representing a potential of $1,534,099 in revenue opportunity. To date, Aethlon has invoiced $3,188,131 to DARPA for achieving fourteen of sixteen milestone objectives targeted in the first two years of the DLT program.
Its been holding at nearly .10 since august 2nd, where do you see that it 'will not hold'?
As far as I know, Chan is doing everything he can to build this company and he doesn't have time to worry about share price at this point, but is confident that his tenacity and patience will pay off handsomely.
There is a lot happening with the company for sure. Just got an email from Darrell Brookstein telling me he's done what he's came to the company to accomplish, and is now moving on to the next phase in his life, getting involved in the next 'big thing'. I asked him to keep me informed, but although he has left, he is holding his shares and is probably the 5th largest shareholder.
Exactly, and our new board member is from amaran, and hails from earlier companies that were bought out by larger pharms.... i see the good writing on the wall
Prior to Optimer, Dr. Che's industrial experience included 20 years in research, management and operations at large companies including Exxon Mobil Corporation, Aventis Pharmaceuticals, Inc., and EniChem S.p.A. She also served as Vice President, Operations of M and D Precision Science Group, Inc. in 1988 and co-founded Cinogen Pharmaceuticals, Inc. (China) serving as Vice President from 1994 to 1996. Cinogen later became a wholly-owned subsidiary of Pharmanex, Inc., where Dr. Che served as Sr. Director of Quality Assurance and Sourcing.
Dr. Che holds bachelors' degrees in chemistry from Illinois State University and #$%$-Jen Catholic University (Taiwan), a Ph.D. in physical-inorganic chemistry from Brandeis University, and did post-doctoral work at Columbia University. She has authored numerous scientific publications and holds over twenty U.S. patents in material synthesis and applications.
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), is very pleased to announce the appointment of Tessie Mary Che, Ph.D. to the Company's Board of Directors.
Dr. Tessie Che is currently Chair of the Board of Directors of Amaran Biotechnology, Inc., a private biotech company based in Taiwan. Stellar's recent US$12 Million Private Placement included a $5 Million investment by Amaran Biotechnology.
"Dr. Che brings to Stellar extensive experience pertinent to our key corporate goals at this high-growth stage," said Frank Oakes, Stellar President and CEO. "She co-founded and successfully led a biopharmaceutical firm from development to commercialization of a new drug product to treat Clostridium difficile. In addition, Dr. Che has extensive scientific and operations acumen, as well as strategic ability transforming research programs and pipelines into high-value business assets."
"It is my pleasure to join Stellar's Board of Directors," said Tessie Mary Che, Ph.D. "Stellar's proprietary strength in KLH protein manufacturing and its vision to target the active immunotherapy market makes this an impressive company with very high commercial potential."
Dr. Che co-founded Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) in 1998 and served over ten years as Optimer's Chief Operating Officer and Senior Vice President of Corporate Affairs. During the process development years of Optimer's flagship drug, DIFICID®, Dr. Che built and led the company's Chemistry, Manufacturing and Quality Control (CMC) teams through the successful and cost-effective registration and commercialization of DIFICID® in the United States, Canada and Europe in 2011.
This is a small 'flyer' holding. Rumors, possibilities and hope...thats all I have, along with my fingers crossed. SBOTF holds higher hopes for sure, AEMD and CTSO possible big upsides... LGNT, not happy with ownership, but a few big sales and everything can change. Good luck to you and your 'lottery' picks too.
Nothing to do with Stellar. Just a holding that I saw news on and posted.
global threats. We would like to thank our loyal shareholders for their continued support as we further expand our Dazer Laser® Product Line, as well as other new technologies currently being worked on.
Laser Energetics, Inc. (PINKSHEETS: LNGT) today announced that they received an international order, which will be accompanied by a substantial down payment, for its Dazer Laser® GUARDIAN and accessories worth more than $650,000 USD, with training costs yet to be incurred. This order was received from a customer in Southwest Asia, which will not be specified at this time for security reasons at the request of the foreign military end-user.
We, at Laser Energetics, are very excited to have another international order, now on a larger scale, realize the true value and solutions provided by the Dazer Laser® GUARDIAN. The GUARDIAN is the only optical distracter (ocular interruptor) in the world that incorporates LEI's patent pending Variable Range and Focus Optics™ technology allowing the operator to both safely and effectively engage the threat at all ranges from one (1) meter out to 1000 meters, and beyond. Robert Battis, President and CEO, added, "We, as a company, are extremely excited to have received this new international order, which is much larger than many of our previous international orders we have received. Laser Energetics looks forward to its very bright future as an industry leader in non-lethal laser weapons intended for the protection of the United States and foreign allies alike."
As previously announced, the Dazer Laser® Team is currently engaged in multiple US Military contracts (i.e. MARCORSYSCOM OI Program), and has recently responded to the US Navy's next generation family of small arms laser aiming modules with the multi-functioning Dazer Laser® STEALTH system. In addition, our Dazer Laser® Team is currently attending the 2013 National Guard Association of the United States (NGAUS) Conference being held in Honolulu, HI, and will be attending key events around the world over the next several months to meet with many of the foreign militaries and governments requesting the needs of the Dazer Laser® to help combat the growing number of global thr
Dr. Gercel-Taylor’s research is directed at investigations that define genetic and epigenetic alterations associated with the development of cancer and how these alterations can be modified by hormones and phytohormones as therapeutic agents alone and in combination with conventional therapies. Her lab’s research focuses on four interrelated areas that evolve around the theme of amplifying the efficacy of therapeutic approaches to cancer and chronic diseases associated with aging in women.
Prognostic indicators in ovarian cancer. Studies are directed at the identification of prognostic indicators to design and monitor therapy, allowing individualization of therapy. This approach facilitates the identification of therapeutic targets and defines mechanisms regulating drug sensitivity and resistance. The incorporation of molecular markers into the pathologic analysis of ovarian cancer will lead to more appropriate use of drugs, reduced morbidity and optimized efficacy.
Cellular response to chemotherapy. Studies are directed to understanding the genetic and epigenetic mechanisms of drug resistance. Use of translational objectives will provide a molecular rationale to guide the choice of therapy and the duration of treatment for individual patients, while defining mechanisms underlying drug resistance will lead to creative approaches for new drug discovery and improved utilization of existing chemotherapies.
Hormone therapy in cardiovascular disease (CVD) and cancer. Studies are directed to determining the mechanism through which combination hormone therapy and its individual components can alter the incidence or recurrence of breast and ovarian cancer, as well as the development of CVD. Differential expression of cellular estrogen receptors (ERα, ERβ and GPR30) have been implicated as key determinants in the cellular responses to exogenous estrogens, which can trigger molecular events leading to chronic diseases.
Complementary and Alternative medical (C
SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Gercel-Taylor will direct and plan the execution of diagnostic clinical programs and interact with collaborative partners and regulatory authorities.
Aethlon Medical develops therapeutic devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Company is preparing to launch the first U.S. studies of the Aethlon Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier® is a first-in-class device that targets the rapid elimination of viruses and cancer glycopathogens, including disease-promoting exosomes from circulation.
Exosome Sciences was recently launched by Aethlon to be a stand-alone organization that pursues exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Dr. Gercel-Taylor stated, "I am very excited to join Exosome Sciences as the Clinical Research Director. This is a very timely opportunity to develop clinically relevant exosome-based assays to enhance patient care with regard to risk assessment, diagnosis and treatment. The conditions are not limited to but include cancer, cardiova